| Affymax Submits NDA For Peginesatide - RTT News |
|
|
RTT News The EMERALD findings suggested that once-monthly peginesatide was similar to epoetin in maintaining hemoglobin levels in CRF patients on dialysis with anemia with a similar adverse event rate. The FDA is expected to decide in 60 days whether to file ... Affymax files for approval of kidney disease drug Forbes Affymax and Takeda Announce the Submission of a New Drug Application for |